You are here:
Pharmaceutical Manufacturing — CDMO & OTC
Last Updated:February 27, 2026
About This Investor
JP-B-402
Mandate summary: From Japan, this investor is open to qualified opportunities. Their focus is: Pharmaceutical formulations (CMO/CDMO), generic formulation development and manufacturing, new drug development and manufacturing, contract manufacturing of new drugs, long – listed products, and large – scale OTC drugs Oral solid dosage forms Injectables. The stated objective is Overseas expansion of existing…
Pharmaceutical Manufacturing (CDMO)
Indonesia, Vietnam
Strategic Expansion
$6.54M - $13.1M
Majority / 100%
Request Full Investor Profile
Similar Investors
JP-B-494
Japan – based, this investor has an active mandate. Their
Facility Services
Malaysia, Philippines, Singapore
Overseas Expansion
$6.54M - $65.4M
100% (base)
JP-B-590
Opportunity mandate: Their focus is: Priority is given to land
Logistics & Warehousing
ASEAN, Philippines, Thailand
Strategic Expansion
$65.4M - $196.3M
Majority / Minority
JP-B-672
Current mandate: Priority theme: Greenfield projects: Renewable energy projects, construction
Renewable Energy (EPC)
ASEAN, India
Diversification
$3.27M - $32.7M
Minority